Skip to content

Re-evaluation of Zhuifengtougu capsule in the treatment of cervical spondylosis

Re-evaluation of Zhuifengtougu capsule in the treatment of cervical spondylosis

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000028807
Enrollment
Unknown
Registered
2020-01-04
Start date
2020-01-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical spondylosis

Interventions

Sponsors

Temporarily not sure
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) aged 18-75 years old; (2) meet the diagnostic criteria of cervical spondylosis.

Exclusion criteria

Exclusion criteria: (1) patients with cervical tuberculosis, tumor or unhealed shoulder and neck fracture; (2) patients with bleeding tendency, gastrointestinal bleeding or other chronic hemorrhagic diseases within one month; (3) patients with allergic constitution or allergic to known components of this drug; (4) pregnant and lactating women; (5) those with serious diseases such as heart, lung, liver, kidney, hematopoietic system and immune system.

Design outcomes

Primary

MeasureTime frame
Score of symptoms and signs related to cervical spondylosis;

Secondary

MeasureTime frame
Cervical spondylosis NPQ neck pain scale;The functional status of the Crista Medulla was evaluated (40 points method);Vas Quantitative Score;Quality of life assessment;

Countries

China

Contacts

Public ContactHe Yanlin

Hinye Pharmaceutical Co., Ltd

767567825@qq.com+86 15084974669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026